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Abstract
Background: Ezrin is highly expressed in skin cancer and promotes tumor metastasis. Ezrin serves as a promising
target for anti-metastasis therapy. The aim of this study is to determine if the flavonoid bacailein inhibits the
metastasis of skin cancer cells through Ezrin.
Methods: Cells from a cutaneous squamous carcinoma cell line, A431, were treated with baicalein at 0-60 μMt o
establish the non-cytotoxic concentration (NCC) range for baicalein. Following treatment with baicalein within this
range, total Ezrin protein (both phosphorylated and unphosphorylated forms) and phosphorylated-Ezrin (phos-Ezrin)
were detected by western blotting, and Ezrin RNA was detected in A431 cells using reverse transcription-polymerase
chain reaction (RT-PCR). Thereafter, the motility and invasiveness of A431 cells following baicalein treatment were
determined using wound-healing and Boyden chamber invasion assays. Short-interfering RNA (si-RNA) specifically
targeting Ezrin was transfected into A431 cells, and a si-RNA Ezrin-A431 cell line was established by G418 selection. This
stable cell line was transiently transfected with Ezrin and mutant Ezrin plasmids, and its motilityand invasiveness was
subsequently determined to clarify whether bacailein inhibits these processes through Ezrin.
Results: We determined the range of NCCs for baicalein to be 2.5-40 μM in A431 cells. Baicalein displayed a dose-
and time-dependent inhibition of expressions of total Ezrin and phos-Ezrin within this range NCCs. In addition, it
exerted this inhibitory effect through the reduction of Ezrin RNA transcript. Baicalein also inhibited the motility and
invasiveness of A431 skin carcinoma cells within the range of NCCs, in a dose- and time-dependent manner. A431
cell motility and invasiveness were inhibited by 73% and 80% respectively when cells were treated with 20 μM
baicalein. However, the motility and invasiveness of A431 cells containing the Ezrin mutant were not effectively
inhibited by baicalein.
Conclusions: Baicalein reduces the migration and invasiveness of A431 cells through the inhibition of Ezrin
expression, which leads to the suppression of tumor metastasis.
Background
Ezrin is a member of the ezrin-radixin-moesin (ERM)
protein family that crosslinks the epithelial cell mem-
brane with cytoskeleton. Ezrin helps maintain cell shape
and motility, binds to adhesion molecules and
participates in the regulation of intracellular signal
transduction [1-4]. It is reported that Ezrin has an
abnormal expression and a modified subcellular localiza-
tion in tumor cells. Ezrin serves as a crosslinking mole-
cule between the membranes of keratinocytes and
cytoskeleton. Interacting with other adhesion molecules,
Ezrin plays an essential part in the development of
tumors, by promoting the proliferation and infiltration
of tumor cells, metastasis, neovascularisation, and other
biological mechanisms involved in malignancy [5-10]. In
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anti-tumor drug target molecule [8-10].
One important mechanism for regulating the function
of Ezrin is through phosphorylation of a conserved
threonine residue in the C terminus of Ezrin protein
(Thr-567) [11-14]. Non-phosphorylated Ezrin exists in a
folded conformation, which results in the masking of its
binding sites for other molecules. Phosphorylation at the
conserved threonine residue causes conformational
changes in Ezrin, unmasking its binding sites [11,14].
Phosphorylation of Ezrin at Thr 567 keeps it open and
active, and prolongs its half-life [11]. Phosphorylated-
Ezrin (phos-Ezrin) may be involved in various functions,
including cell adhesion and motility, as well as the orga-
nization of cell surface structure.
Baicalein (5,6,7-trihydroxy-2-phenyl-4H-1-benzopyran-
4-one) is one of four major flavanoids found in Scutel-
laria baicalensis G e o r g i ,a nh e r bw i d e l yu s e dt ot r e a t
various inflammatory diseases and ischemia [15]. In
addition to its effectiveness against free radicals, baica-
lein has been reported to have a variety of other func-
tions [16,17]. Recently, baicalein was discovered to have
anti-cancer activity through inhibition of the Phosphoi-
nositide 3-kinase (PI3K) pathway [18]. It also exerts
proapoptotic activity through reactive oxygen species
(ROS)-mediated and Ca
2+-dependent mitochondrial dys-
function pathways in various cell types [19]. Bacailein
has an inhibitory effect on lung cancer [20], colorectal
cancer [21], gastric cancer [22], ovarian cancer [23],
breast cancer [24], prostate cancer, and skin cancer
[25,26]. Baicalein was also shown to inhibit the Epstein-
Barr virus (EBV) early antigen activation induced by 12-
O-tetradecanoylphorbol-13-acetate, and inhibit mouse
skin tumors in an in vivo two-stage carcinogenesis
model [27]. In particular, it was found that its anti-
tumor effects in skin cancer were associated with inhibi-
tion of the p12-LOX pathway [28]. However, little is
known about the molecular mechanisms of its anti-
metastatic effects. Here, we show a novel anti-metastatic
mechanism for baicalein in skin cancer cells, through
inhibition of Ezrin and phos-Ezrin in A431 cells.
Methods
Reagents and antibodies
Chemical reagents, including dimethyl sulfoxide (DMSO),
Tris, HCl, sodium dodecyl sulfate, and MTT [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxyme-thoxyphenyl)-2-(4-
ulfophenyl)-2H-tetrazolium] were purchased from Sigma-
Aldrich (St.Louis, MO). Baicalein was purchased from
Sigma-Aldrich (St.Louis, MO), and stored at 4°C under
dark conditions. The stock solution of baicalein for incu-
bation with cells was prepared in DMSO and further
diluted in the culture medium. The final DMSO concen-
tration in the medium was 0.1% (in control or treated
samples), which did not affect cell viability. TRIozl reagent
was purchased from Invitrogen. Antibody against Ezrin
was purchased from Covance (Berkeley, CA), antibody
against phosphorylated Ezrin at Thr-567 (phos-Ezrin Thr-
567) was purchased from Cell Signaling Technology (Dan-
vers, MA) and antibodies against b-actin and normal
mouse immunoglobulin G (IgG) were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The sec-
ondary antibodies horseradish peroxidase-linked anti-
mouse IgG and anti-rabbit IgG were purchased from
Santa Cruz Biotechnology, Inc. The protein assay kit was
purchased from Bio-Rad (Herndon, VA).
Cell culture and baicalein treatment
A431 cells (human squamous carcinoma cell line) were
purchased from the Shanghai Cell Biological Institute of
the Chinese Academy of Science (Shanghai 200007,
China). The cell line was cultured as a monolayer in
RPMI-1640 medium containing 10% fetal bovine serum, 2
mM L-glutamine, 100 μg/ml penicillin, 100 mg/ml strep-
tomycin (Invitrogen, Carlsbas, CA), and maintained in an
incubator with a humidified atmosphere of 95% air and
5% CO2 at 37°C. For baicalein treatment, appropriate
amounts of stock solution of baicalein were added to the
cultured cells to achieve the indicated concentrations and
then incubated for the indicated time points. Following
baicalein treatment, cell viability was determined using
MTT assays. To determine if baicalein inhibited Ezrin and
phos-Ezrin in a dose-dependent manner, A431 cells were
treated with 10, 20, and 40 μM baicalein for 24 h. To
determine if baicalein inhibited Ezrin and phos-Ezrin in a
time-dependent manner, A431 cells were treated with 20
μM baicalein for 24, 48, and 72 h. After treatment with
baicalein, the cells were harvested, and proteins were
extracted from the cell samples. Expressions of Ezrin and
phos-Ezrin were detected by western blotting.
Determination of cell viability (MTT assay)
To evaluate the cytotoxicity of baicalein, MTT assays
were performed to determine cell viability. A431 cells
were seeded in 96-well plates at a density of 3.5 × 10
3
cells/well and treated with baicalein at 0-60 μM concen-
trations at 37°C for 48 h. After the exposure period, cell
media was removed, and cells were washed with phos-
phate-buffered saline (PBS). Thereafter, the media was
changed and cells were incubated with 100 μlM T T( 5
mg/ml) for 4 h. The total number of viable cells per
dish is directly proportional to the production of forma-
zan, which was solubilized in isopropanol, and measured
spectrophotometrically at 563 nm [29].
Western blotting analysis
After treatment with baicalein, cell samples were dis-
rupted with 0.6 ml lysis buffer (1 × PBS, 1% Nonidet P-
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fate, 100 μg/ml phenylmethanesulfonyl fluoride, 10 μg/
ml aprotinin, and 1 mM sodium orthovanadate). The
cell lysate was then subjected to a centrifugation of
10,000× g for 10 min at 4°C. The supernatant protein
concentration of each sample was determined using the
Bio-Rad Protein Assay (Bio-Rad Laboratories, Inc., Her-
cules, CA). Protein (40 μg) from each sample was sepa-
rated using a 10% polyacrylamide gel and transferred
onto a nitrocellulose membrane. The blot was subse-
quently incubated with 5% non-fat milk in PBS for 1 h
to block non-specific binding, and incubated with speci-
fic antibodies against Ezrin (Covance) or phos-Ezrin
(Cell Signaling Technology) for 2 h and incubated with
an appropriate peroxidase-conjugated secondary anti-
body (Sigma, St. Louis, MO) for 1 h. All incubations
were carried out at 37°C. The blot was washed 3 times
in PBS, and the signal was developed using 4-chloro-1-
napthol/3,3-o-diaminobenzidine. The relative photo-
graphic density was quantified by scanning the photo-
graphic negative using a gel documentation and analysis
system. b-actin was used as an internal control to verify
basal protein expression levels of Ezrin and phos-Ezrin,
as well as equal protein loading.
RT-PCR for detecting Ezrin RNA
To detect Ezrin RNA in A431 cells following baicalein
treatment, we performed reverse transcription-polymer-
ase chain reaction (RT-PCR). A431 cells were initially
treated with baicalein at various concentrations (5, 10,
20, and 40 μM) for 48 h. The cell samples were then
harvested, and RNAs in these samples were extracted
using TRIozl and following the manufacturer’s suggested
protocol (Invitrogen). For detecting Ezrin RNA, primers
for PCR were designed based on GenBank sequences for
full-length human Ezrin and b-actin cDNA. The follow-
ing primer sequences were used: for ezrin, primer 1
(sense) 5’-CTCATCCAGGACATCACCCA-3’,p r i m e r 2
(antisense) 5’-TCACTCCAAGGAAAG CCAAT 3’.T h e
corresponding PCR product was 450 bp. For b-actin,
primer 3 (sense), 5’-GACAGGATGCAGAAGGAGAT-
3’, primer2 (antisense) 5’-TGTGTGGACTTGGGAG
AGGACT-3’. The corresponding PCR product was 550
bp. The PCR products were visualized using agarose gel
electrophoresis. Following electrophoresis, the relative
PCR product band densities were quantified by densito-
metry using ImageQuant image analysis system (Storm
Optical Scanner, Molecular Dynamics). b-actin was used
as an internal control to verify the basal expression level
of Ezrin and equal RNA loading.
Wound-healing assays
A431 and si-RNA Ezrin-A341 cells (2 × 10
6)w e r e
seeded in 10-mm plates at 37°C for 24 h. Confluent
monolayer of A431 was then wounded using a plastic
tip. Cells were treated with baicalein at 20 μM, and then
photographed after 48 h. Cells moving cross the bound-
aries lines were counted.
Cell invasion and motility assay
For cell invasion assay, A431 cells were treated with dif-
ferent concentrations of baicalein. After 24 h of treat-
ment, cells were removed by trypsinization, and their
invasiveness was tested in vitro using a Boyden chamber
invasion assay [30]. Matrigel (Collaborative Biomedical
Products, Bedford, MA) was diluted to 0.5 mg/ml with
cold filtered distilled water and applied to 8-mm pore
size polycarbonate membrane filters. Treated cells were
seeded in a Boyden chamber (Neuro Probe, Cabin John,
M D )a tad e n s i t yo f1 . 5×1 0
4 cells/well in 50 μlo f
serum-free-medium in the top well of the chamber and
then incubated for 12 h at 37°C. The bottom well con-
tained standard medium with 20% fetal bovine serum.
The cells that invaded the lower surface of the mem-
brane were fixed with methanol and stained with hema-
toxylin and eosin. Random fields were counted for cells
that had invaded the membrane, using an optics micro-
scope. To determine the effect of baicalein on cell moti-
lity, cells were seeded in a Boyden Chamber on
membrane filters, which were not coated with Matrigel.
The motility of cells treated or untreated with baicalein
was measured as previously described [30]. The statisti-
cal analysis was corrected for cell viability to clarify the
effect of baicalein.
Construction of expression vectors
A full-length Ezrin DNA fragment was generated by
PCR and subcloned into a pcDNA3.1 vector (Amersham
Biosciences Corp., Piscataway) to generate a pcDNA3.1-
Ezrin plasmid [29]. A plasmid containing a mutant form
of Ezrin (pcDNA3.1-Ezrin M) was generated with the
QuickChange II site-directed mutagenesis kit and Ezrin
mutant primers: Primer 1 (sense), 5’-CAGGGCAACGC-
CAAGCAGCGCAT-3’; Primer 2 (antisense), 5’-
ATGCGCTGCTTGGCGTTGCCCTG-3’ (Thr567 was
muted into Ala 567). The pU6pro vector was used to
construct a non-specific control vector containing a
scrambled sequence (si-mock), as well as two si-RNA
vectors specifically targeting Ezrin (si-Ezrin). The
pU6pro-si-mock and pU6pro-si-Ezrin vectors were gen-
erated following the manufacturer’s recommended pro-
tocol. Primers were synthesized for si-mock (general
scramble: sense, 5’-TTTGACTACCGTTGTTA-
TAGGTGTTCAAGAGACACC TATAACAACGG-
TAGTTTTTT-3’;a n t i s e n s e ,5 ’-CTAGAAAAAACTA
CCGTTGTTAT AGGTGTCTCTTGAACACCTATAA-
CAACGGTAGT-3’)a n ds i - E z r i n( S e t1 ,5 ’-CCCCAAA-
GATTGG CTTTCC-3’ (position in the open reading
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TAA-3’ (open reading frame, 140-158) (Ambion, Texas)
[29]. All constructs were confirmed by restriction
enzyme mapping and DNA sequencing.
Generation of stable cell lines
A431 cells (5.0 × 10
5) were transfected with pU6pro-si-
Ezrin constructs using Lipofectamine2000 reagent (Life
Technologies, Inc.) following the manufacturer’ss u g -
gested protocol. si-RNA Ezrin-A341 stably-transfected
cell lines were obtained by selection for G418 resistance
(400 μg/ml). Ezrin knockdown was confirmed by asses-
sing Ezrin expression. si-RNA Ezrin-A341 cell lines
were transiently transfected with 4 μgo fp c D N A 3 . 1 ,
pcDNA3.1-Ezrin, or pcDNA3.1-Ezrin M. After baicalein
treatment, the invasion and motility of these stably-
transfected cell lines were determined using a Boyden
chamber invasion assay.
Statistical analysis
Each assay was performed in triplicate. Data are
expressed as the mean ± standard deviation (SD). The
statistical significance of the data obtained were evalu-
ated using the Student’s t-test (* p < 0.05).
Results
Cytotoxicity assay for baicalein in skin cancer cells
Baicalein is a flavonoid found in Scutellaria baicalensis
Georgi, which is the aglycone compound of baicaline.
Its chemical structure is showed in Figure 1a. In this
study, we determined the cytotoxicity of baicalein by
treating A431 cells with various concentrations of baica-
lein for 48 h. Compared with the control treatment
(0.1% DMSO), the cell viability of the samples treated
with baicalein at concentrations between 2.5-40 μMw a s
not significantly altered (Figure 1b), indicating that bai-
calein was not cytotoxic to A431 cells at these dosages.
Hence, 2.5-40 μM was determined to be a range of the
non-cytotoxic concentration (NCC) of bacailein on
A431 cells. This range of concentrations was therefore
applied in all subsequent experiments.
Suppression of Ezrin expression by baicalein
To determine if baicalein had an inhibitory effect on
Ezrin, a NCC of baicalein (10-40 μM) was used to treat
A431 cells, and then total Ezrin and phos-Ezrin expres-
sion levels were detected with western blotting. After
baicalein treatment, total Ezrin and phos-Ezrin expres-
sion levels dramatically decreased compared with the
control (Figure 2a, lane 1 vs 2, 3, 4 in the upper and
middle panels), and this decrease was dose-dependent.
To determine if this inhibition was dependent on the
length of time, 20 μM baicalein was used to treat A431
cells for 12, 24, and 48 h, and total Ezrin and phos-
Figure 1 Effect of baicalein on the viability of A431 cells.a .
Structure of baicalein, which is the aglycone compound of
baicaline. b. A431 cells were treated with 0, 2.5, 5, 10, 20, 40, 50, or
60 μM of baicalein for 48 h before being subjected to an MTT assay
for cell viability. Data were represented as the mean ± SD from
three independent experiments. Baicalein had no cytotoxic effect
on A431 cells at a range of 2.5-40 μM. Results were statistically
analyzed with a Student’s t-test (*p < 0.05). The error bars represent
SDs.
Figure 2 The inhibitory effects of baicalein on Ezrin and phos-
Ezrin in A431 cells. a. A431 cells were treated with baicalein at 0,
10, 20, and 40 μM for 24 h. b. A431 cells were treated with 20 μM
baicalein for 12, 24, and 48 h. After baicalein treatment, total protein
was extracted from these cell samples. The protein samples were
then subjected to western blotting, and the levels of Ezrin and
phos-Ezrin expression in these samples were determined. Baicalein
inhibited the expression of Ezrin and phos-Ezrin at Thr-567 in a
dose- and time-dependent manner. b-actin or Ezrin respectively
served as the control for quantifying Ezrin or phos-Ezrin. Three
independent experiments were carried out and representative
figures are shown.
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gest that the inhibitory effect of baicalein on total Ezrin
and phos-Ezrin was time-dependent (Figure 2b, lane 1
vs 2, 3, 4 in the upper and middle panels). To determine
if the inhibitory effect of baicalein on Ezrin protein
expression occurs through downregulation of Ezrin
RNA, Ezrin RNA expression was detected in A431 cells
treated with baicalein using RT-PCR. Following baica-
lein treatment, Ezrin RNA expression dramatically
decreased in a dose-dependent manner (Figure 3a, lane
2 vs 3, 4, 5, 6, and Figure 3b, lane 1 vs.2 ,3 ,4 ,5 ) .
Inhibitory effect of baicalein on the motility and
invasiveness of A431 cells
Ezrin is associated with cell motility in tumor invasion.
As a first step towards examining the effect of baicalein
on Ezrin expression and function, we investigated
whether baicalein could inhibit the invasion and motility
of A431 cells in vitro. We used wound-healing assays to
test the migration of A431 cells with baicalein
treatment. Following baicalein treatment, the motility of
A431 cells was significantly inhibited, and consequently
the cells were unable to migrate into the wound (Figure
4, panel a vs. b and lane 1 vs. 2 in panel c, *p < 0.05).
Same as Figure 4-(b), the crawling movement of cells
was also inhibited when transfected with Ezrin si-RNA
(Figure 4-c). Ezrin expression dramatically decreased fol-
lowing baicalein treatment and Ezrin si-RNA transfec-
tion (Figure 4-e). There were virtually no scratches
across the boundaries and the migration of A431 cells
was not observed. Hence, we concluded that there was
no significant difference in the migration of Ezrin si-
RNA transfected cells and cells treated with baicalein.
To examine the invasiveness of A431 cells following
baicalein treatment, a Boyden chamber coated with
Matrigel was used. The results suggested that the num-
ber of cells that invaded the lower chamber was signifi-
cantly reduced by baicalein treatment (Figure 5A-b;
Figure 5A-c, lane 2 *p < 0.05). The observed reduction
was concentration-dependent, with 80% inhibition
occurring when 20 μM baicalein was used (Figure 5A-
c). A similar inhibitory effect was also observed for the
mobility of baicalein-treated cells. To further test the
time and dose-dependence of the inhibitory effects
observed, A431 cells were treated with baicalein at var-
ious concentrations or time points, and then subjected
to analyses for motility and invasiveness. After baicalein
Figure 3 Inhibitory effect of baicalein on Ezrin RNA in A431
cells. A431 cells were treated with baicalein at 0, 5, 10, 20, and 40
μM for 48 h. After baicalein treatment, the cell samples were
harvested, and RNAs in these samples were extracted. Ezrin RNA
expression was detected by RT-PCR. 0.1% DMSO served as the blank
control. b-actin served as the loading control. The expression of
Ezrin RNA in A431 cells gradually decreased with increasing
baicalein concentrations. Three independent experiments were
carried out and representative figures are shown.
Figure 4 Inhibitory effects of baicalein on A431 cell migration.
A431 cells (2 × 10
6) were seeded in 10-mm plates and incubated at
37°C for 48 h. Confluent monolayers of A431 cells were then
wounded using a plastic tip. The cells were treated with 20 μM
baicalein, then photographed after 48 h. The cells migrating cross
the boundaries lines in the center of the wells were counted, and
Ezrin expression was examined in the cell samples. (a) A431 cells
treated with 0.1% DMSO. (b) A431 cells treated with 20 μM
baicalein. (c) A431 cells transfected with Ezrin si-RNA. (d) Numbers
of cells that moved cross the lines (10 fields). (e) Ezrin expression in
A431 cells with 0.1% DMSO, 20 μM baicalein or Ezrin si-RNA,
respectively. The data are represented as the mean ± SD from three
independent experiments. Results were statistically analyzed using
one-way analysis of variance (ANOVA) with a post hoc Dunnett’s
test (* p < 0.05). The error bars represent SDs.
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were decreased in a dose-dependent manner, there was
only 27% mobility and 21% invasion when cells were
treated with 20 μM baicalein, and 16% motility and in
11% invasion when treated with 40 μM baicalein (Figure
5B, C, *p < 0.05). The cells also displayed a time-depen-
dent reduction in these properties (Figure 5D, E, *p <
0.05, **p < 0.01). Hence, these results indicated that bai-
calein could inhibit A431 cell migration and invasiveness
in a dose and time-dependent manner.
Suppression of the migration and invasiveness of A431
cells by baicalein through Ezrin
To test if the reduction of motility and invasiveness of
A431 cells by baicalein occurs through Ezrin, si-RNA
targeting Ezrin was transfected into A431 cells. si-RNA
Ezrin-A431 cells were then transiently transfected with
pcDNA3.1, pcDNA3.1-Ezrin M or pcDNA3.1-Ezrin and
then treated with 20 μM baicalein for 48 h. The motility
and invasiveness of the cells were then evaluated. Fol-
lowing baicalein treatment, the invasiveness and motility
of cells transfected with pcDNA3.1-Ezrin dramatically
decreased compared with the control-transfected cells
(Figure 6b, lane 5 vs. 6, and Figure 6c, lane 5 vs.6 ,* p<
0.01). Ezrin expression was also decreased compared
with control cells (Figure 6a, lane 5 vs. 6 in the upper
panel). si-RNA Ezrin-A431 cells transfected with
pcDNA3.1-Ezrin M did not show decreased motility and
invasiveness (Figure 6b, lane 3 vs. 4, and Figure 6c, lane
3 vs. 4). In the transfects with pcDNA3.1-Ezrin M, Ezrin
expression decreased when baicalein treatment (Figure
6a, lane 3 vs. 4), and baicalein degraded Ezrin expres-
sion, but the motility and invasion of cells did not alter
(Figure 6b, lane 3 vs.4 ,a n dF i g u r e6 c ,l a n e3vs.4 ) .
These data suggest that baicalein inhibits Ezrin expres-
sion, and consequently decreases the invasiveness and
migration of skin cancer cells.
Discussion
Ezrin is overexpressed in a variety of neoplastic cells
including skin cancers [31], and is involved in the later
stages of tumor progression and metastasis. It is
expressed in most primary melanomas of the skin and
in all metastatic tumors. Ezrin expression correlates
with tumor thickness and level of invasion, which sug-
gests an association between Ezrin expression and
tumor progression [32]. The intensity of Ezrin immu-
noreactivity was found to increase with tumor size, as
measured by tumor thickness (Breslow classification)
and invasion to dermal layers (Clark classification) [33].
The assessment of Ezrin expression may be exploited as
a new tool to evaluate the malignancy of human mela-
noma. In addition, gene therapy or drug treatments
aimed at inhibiting actin assembly to the phagosomal
membranes may be proposed as a new strategy for the
control of tumor aggressiveness [34].
Baicalein, a major flavonoid from a traditional Chinese
herb Scutellaria baicalensis Georgi (Huangqin), which is
the aglycone compound of baicaline, possesses potent
anti-cancer properties. It has been reported that baica-
lein inhibited mouse skin tumors in an in vivo two-stage
carcinogenesis model [27]. Pretreatment of mouse skin
with various amounts of baicalein caused inhibition of
H2O2 and myeloperoxidase formation by 12-O-tetrade-
canoylphorbol-13-acetate. These results indicate that
baicalein serves as a potential cancer-chemopreventive
agent against tumors [25]. In the present work, A431, a
human epithelial carcinoma cell line with high malig-
nancy and high expression of Ezrin, was used to investi-
gate the inhibitory mechanism of baicalein. To
distinguish anti-cancer effects from cytotoxicity to cells,
Figure 5 Inhibitory effects of baicalein on the motility and
invasiveness of A431 cells. A431 cells were treated with 20 μM
bacailein, and cell invasiveness was detected using Boyden
Chamber with Matrigel coating. A-(a), Invasiveness of control cells
(treated with 0.1% DMSO). A-(b), Invasiveness of cells treated with
20 μM baicalein. Scale bar, 10 μm. A-(c), Numbers of cells invading
through the filters of chamber (10 fields). To test for dose-
dependence, A431 cells were treated with baicalein at 20 or 40 μM
for 48 h, and for the time-course experiment, A431 cells were
treated with 20 μM baicalein for 24, 48, and 72 h. The cells were
then subjected to analyses for motility and invasion abilities as
described in Methods. B. Motility of A431 cells at various
concentrations of baicalein. C. Invasiveness of A431 cells at various
concentrations of baicalein. D. Motility of A431 cells at various time
points. E. Invasion of A431 cells at various time points. The data are
represented as the mean ± SD from three independent
experiments. Results were statistically analyzed using one-way
ANOVA with post hoc Dunnett’s test (* p < 0.05). The error bars
represent SDs. IR, invasion rate. MR, motility rate.
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used on A431 cells. We determined 0-40 μMt ob et h e
range of NCCs that could be used. We next set out to
test if baicalein had an inhibitory effect on Ezrin. We
found that Ezrin expression was effectively inhibited by
baicalein. In addition, Ezrin function was previously
reported to be regulated by phosphorylation of Thr-567
at its C-terminus [11-14]. We found that baicalein could
effectively inhibit the phosphorylation of Ezrin at Thr-
567 of C terminus. Furthermore, baicalein exerted its
inhibitory effect by suppressing the Ezrin RNA tran-
script. Based on the above results, we believe that baica-
lein specifically inhibits Ezrin expression and
phosphorylation.
Ezrin is involved in a variety of cellular functions,
including cell adhesion, motility, and the organization of
cell surface structure [3,4]. We speculate that baicalein
represses Ezrin expression at RNA transcript, and
reduces Ezrin and phos-Ezrin protein expression, inhi-
bits cell migration and tumor invasion. Interestingly,
baicalein had no effect on the motility and invasiveness
of A431 cells transfected with a mutant form of Ezrin
Ala 567. Although Baicalein also inhibited Ezrin expres-
sion in the transfect with pcDNA3.1-Ezrin M, baicalein
may degrade Ezrin expression, the motility and invasion
of cells did not alter after bacailein treatment. Baicalein
may inhibit 6-10B cell migration and invasion mainly
through reducing phos-Ezrin at Thr 567. These results
indicate that baicalein mediates the reduction of migra-
tion and invasiveness of A431 cells through phos-Ezrin
at Thr567. Baicalein may serves as a novel drug for skin
cancer therapy in the future.
Conclusion
Here, we provide evidence that baicalein inhibits the
invasive abilities of skin cancers through Ezrin. Baica-
lein inhibits the migration and invasiveness of A431
cells, following the reduction of Ezrin, phos-Ezrin and
Ezrin RNA. However, baicalein had no effect on A431
cells transfected with an Ezrin mutant at 567, suggest-
ing that its inhibitory effect on cell migration and
tumor invasiveness occurs mainly through phos-Ezrin
at Thr 567.
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